Common Stock
ARTIVA BIOTHERAPEUTICS INC
NASDAQ:ARTV (9/6/2024, 8:00:03 PM)
12.02
+0.11 (+0.92%)
Artiva Biotherapeutics Inc is a US-based company operating in Biotechnology industry. The company is headquartered in San Diego, California and currently employs 81 full-time employees. The company went IPO on 2024-07-19. Artiva Biotherapeutics, Inc. is a clinical-stage biotechnology company focused on developing natural killer (NK) cell-based therapies for patients suffering from devastating autoimmune diseases and cancers. The firm's product candidates are derived from donor cells (allogeneic) rather than a patient's own cells (autologous) and are pre-manufactured, stored frozen and ready to ship to a patient's treatment location. Its lead product candidate, AlloNK, is being evaluated in combination with B-cell targeted monoclonal antibodies (mAbs) in patients with autoimmune diseases and cancers, such as LN, RA, PV, the ANCA-associated vasculitis subtypes GPA/MPA, SLE and B-NHL. AlloNK is a non-genetically modified, cryopreserved NK cell therapy being evaluated in combination with B-cell targeted mAbs in an ongoing Phase I/Ib trial in class III or IV lupus nephritis (LN) and a basket investigator-initiated trial (IIT) in multiple autoimmune indications.
ARTIVA BIOTHERAPEUTICS INC
5505 Morehouse Drive
San Diego CALIFORNIA
P: 18582674467
Employees: 81
Website: https://www.artivabio.com/
Artiva Biotherapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights...
Artiva's revolutionary cell therapies could be a patient lifeline and a goldmine for investors.
Artiva's revolutionary cell therapies could be a patient lifeline and a goldmine for investors.
Artiva Biotherapeutics Inc. shares jumped 30% in the company’s trading debut after raising $167 million in an expanded initial public offering.
Here you can normally see the latest stock twits on ARTV, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: